Sign up to receive Dana-Farber Spotlight, our email newsletter.View the current issueSubscribe nowUnsubscribe from mailings
Ellen BerlinDirector of Media Relations617firstname.lastname@example.org
Molly McHaleAssociate Director of Media Relations617email@example.com
E. Krop led a study showing that the anti-body drug ado-trastuzumab emtansine
significantly prolonged progression-free survival in patients with progressive
HER2-positive advanced breast cancer.
Eric P. Winer co-chaired an expert panel that developed a clinical practice
guideline on disease management for patients with advanced HER2-positive breast
cancer and brain metastases.
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: